201 related articles for article (PubMed ID: 19058032)
21. HRPT2 gene analysis and the diagnosis of parathyroid carcinoma.
Cetani F; Pardi E; Banti C; Borsari S; Ambrogini E; Vignali E; Cianferotti L; Viccica G; Pinchera A; Marcocci C
Expert Rev Endocrinol Metab; 2008 May; 3(3):377-389. PubMed ID: 30754207
[TBL] [Abstract][Full Text] [Related]
22. Understanding the genetic basis of parathyroid carcinoma.
Gill AJ
Endocr Pathol; 2014 Mar; 25(1):30-4. PubMed ID: 24402736
[TBL] [Abstract][Full Text] [Related]
23. Novel HRPT2/CDC73 gene mutations and loss of expression of parafibromin in Chinese patients with clinically sporadic parathyroid carcinomas.
Wang O; Wang C; Nie M; Cui Q; Guan H; Jiang Y; Li M; Xia W; Meng X; Xing X
PLoS One; 2012; 7(9):e45567. PubMed ID: 23029104
[TBL] [Abstract][Full Text] [Related]
24. CDC73/HRPT2 CpG island hypermethylation and mutation of 5'-untranslated sequence are uncommon mechanisms of silencing parafibromin in parathyroid tumors.
Hahn MA; Howell VM; Gill AJ; Clarkson A; Weaire-Buchanan G; Robinson BG; Delbridge L; Gimm O; Schmitt WD; Teh BT; Marsh DJ
Endocr Relat Cancer; 2010 Mar; 17(1):273-82. PubMed ID: 20026646
[TBL] [Abstract][Full Text] [Related]
25. Molecular Characteristics of Large Parathyroid Adenomas.
Agarwal A; Pradhan R; Kumari N; Krishnani N; Shukla P; Gupta SK; Chand G; Mishra A; Agarwal G; Verma AK; Mishra SK
World J Surg; 2016 Mar; 40(3):607-14. PubMed ID: 26669787
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic performance of parafibromin immunohistochemical staining for sporadic parathyroid carcinoma: a meta-analysis.
Hu Y; Liao Q; Cao S; Gao X; Zhao Y
Endocrine; 2016 Dec; 54(3):612-619. PubMed ID: 27250989
[TBL] [Abstract][Full Text] [Related]
27. A Young Male with Parafibromin-Deficient Parathyroid Carcinoma Due to a Rare Germline HRPT2/CDC73 Mutation.
Kapur A; Singh N; Mete O; Hegele RA; Fantus IG
Endocr Pathol; 2018 Dec; 29(4):374-379. PubMed ID: 30361844
[TBL] [Abstract][Full Text] [Related]
28. Hyperparathyroidism-jaw tumor syndrome: a report of three large kindred.
Iacobone M; Masi G; Barzon L; Porzionato A; Macchi V; Ciarleglio FA; Palù G; De Caro R; Viel G; Favia G
Langenbecks Arch Surg; 2009 Sep; 394(5):817-25. PubMed ID: 19529956
[TBL] [Abstract][Full Text] [Related]
29. Parafibromin, product of the hyperparathyroidism-jaw tumor syndrome gene HRPT2, regulates cyclin D1/PRAD1 expression.
Woodard GE; Lin L; Zhang JH; Agarwal SK; Marx SJ; Simonds WF
Oncogene; 2005 Feb; 24(7):1272-6. PubMed ID: 15580289
[TBL] [Abstract][Full Text] [Related]
30. Downregulation of CASR expression and global loss of parafibromin staining are strong negative determinants of prognosis in parathyroid carcinoma.
Witteveen JE; Hamdy NA; Dekkers OM; Kievit J; van Wezel T; Teh BT; Romijn JA; Morreau H
Mod Pathol; 2011 May; 24(5):688-97. PubMed ID: 21240254
[TBL] [Abstract][Full Text] [Related]
31. Tumor suppressor gene mutation in a patient with a history of hyperparathyroidism-jaw tumor syndrome and healed generalized osteitis fibrosa cystica: a case report and genetic pathophysiology review.
Parfitt J; Harris M; Wright JM; Kalamchi S
J Oral Maxillofac Surg; 2015 Jan; 73(1):194.e1-9. PubMed ID: 25511968
[TBL] [Abstract][Full Text] [Related]
32. HRPT2 mutational analysis of typical sporadic parathyroid adenomas.
Krebs LJ; Shattuck TM; Arnold A
J Clin Endocrinol Metab; 2005 Sep; 90(9):5015-7. PubMed ID: 15956079
[TBL] [Abstract][Full Text] [Related]
33. Para This, Fibromin That: The Role of CDC73 in Parathyroid Tumors and Familial Tumor Syndromes.
Ababneh E; Nosé V
Surg Pathol Clin; 2023 Mar; 16(1):97-105. PubMed ID: 36739170
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic significance of parafibromin expression in parathyroid carcinoma.
Gao Y; Wang P; Lu J; Pan B; Guo D; Zhang Z; Wang A; Zhang M; Sun J; Wang W; Liang Z
Hum Pathol; 2022 Sep; 127():28-38. PubMed ID: 35654240
[TBL] [Abstract][Full Text] [Related]
35. Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma.
Tan MH; Morrison C; Wang P; Yang X; Haven CJ; Zhang C; Zhao P; Tretiakova MS; Korpi-Hyovalti E; Burgess JR; Soo KC; Cheah WK; Cao B; Resau J; Morreau H; Teh BT
Clin Cancer Res; 2004 Oct; 10(19):6629-37. PubMed ID: 15475453
[TBL] [Abstract][Full Text] [Related]
36. Update on parathyroid carcinoma.
Cetani F; Pardi E; Marcocci C
J Endocrinol Invest; 2016 Jun; 39(6):595-606. PubMed ID: 27001435
[TBL] [Abstract][Full Text] [Related]
37. Overview of the 2022 WHO Classification of Parathyroid Tumors.
Erickson LA; Mete O; Juhlin CC; Perren A; Gill AJ
Endocr Pathol; 2022 Mar; 33(1):64-89. PubMed ID: 35175514
[TBL] [Abstract][Full Text] [Related]
38. Hyperparathyroidism 2 gene (HRPT2, CDC73) and parafibromin studies in two patients with primary hyperparathyroidism and uncertain pathological assessment.
Cetani F; Pardi E; Ambrogini E; Banti C; Viacava P; Borsari S; Bilezikian JP; Pinchera A; Marcocci C
J Endocrinol Invest; 2008 Oct; 31(10):900-4. PubMed ID: 19092296
[TBL] [Abstract][Full Text] [Related]
39. Upregulation of FGFR1 expression is associated with parathyroid carcinogenesis in HPT-JT syndrome due to an HRPT2 splicing mutation.
Lee JY; Kim SY; Mo EY; Kim ES; Han JH; Maeng LS; Lee AH; Eun JW; Nam SW; Moon SD
Int J Oncol; 2014 Aug; 45(2):641-50. PubMed ID: 24889687
[TBL] [Abstract][Full Text] [Related]
40. Characterization of a novel CDC73 gene mutation in a hyperparathyrodism-jaw tumor patient affected by parathyroid carcinoma in the absence of somatic loss of heterozygosity.
Ciuffi S; Cianferotti L; Nesi G; Luzi E; Marini F; Giusti F; Zonefrati R; Gronchi G; Perigli G; Brandi ML
Endocr J; 2019 Apr; 66(4):319-327. PubMed ID: 30799315
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
